Insilico and TaiGen Celebrate Clinical Milestone for CKD Anemia Treatment ISM4808 Insilico Medicine and TaiGen Biotechnology announce the successful completion of first human enrollment for ISM4808, a new CKD anemia treatment.

Insilico and TaiGen Celebrate Clinical Milestone for CKD Anemia Treatment ISM4808 #None #Insilico_Medicine #CKD_Anemia #TaiGen_Biotechnology

Insilico Medicine and TaiGen Partner to Combat Chronic Kidney Disease Anemia with Innovative AI Therapies Insilico Medicine and TaiGen join forces to advance ISM4808, an AI-developed inhibitor for treating anemia in chronic kidney disease, aiming to enhance patient care.

Insilico Medicine and TaiGen Partner to Combat Chronic Kidney Disease Anemia with Innovative AI Therapies #None #Insilico_Medicine #TaiGen #CKD_Anemia